Adults 18 to 80, any sex, with Cerebrovascular Accident. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Fugl-Meyer (FM) Motor Assessment of the Upper ExtremityPrimary· Baseline, Post-intervention evaluation at 3 weeks, and 3-month evaluation after the end of intervention
We measure the change of the Fugl-Meyer Motor Assessment scores from the baseline evaluation to the 3-month follow up evaluation after the end of intervention. Fugl-Meyer is a 66-point scale measuring the movement pattern of the upper extremities. For the study, we analyze the total score only. The higher scores indicate a better outcome.
Baseline Evaluation
Group
Value
95% CI
The LARA Therapy
28.5
± 11.6
The Standard Therapy
27.4
± 14.7
Change in Post therapy Evaluation
Group
Value
95% CI
The LARA Therapy
14.2
± 10.8
The Standard Therapy
7.9
± 3.8
Change in 3-month post-intervention
Group
Value
95% CI
The LARA Therapy
18.8
± 12.5
The Standard Therapy
14.1
± 7.4
Modified Ashworth Spasticity ScaleSecondary· Baseline, Post-intervention evaluation at 3 weeks, and 3-months after the end of intervention
We measure the spasticity of the upper extremity at baseline, post-intervention, and at the 3-month follow up evaluation. Spasticity is described as the resistance to passive movement. Participants are asked to relax and evaluators assess muscle resistance to passive movement at one joint at a time: Shoulder, Elbow, Wrist, and Fingers. The evaluator will then grade the resistance on a 6-point scale for each joint. Higher scores indicate more rigid movement or more muscle tone resistance. The minimum score is zero and the maximum score is 4. For this study, we combine all subscores from each jo
Baseline Evaluation
Group
Value
95% CI
The LARA Therapy
0.64
± 0.64
The Standard Therapy
0.56
± 0.61
Post-Intervention Evaluation
Group
Value
95% CI
The LARA Therapy
0.47
± 0.56
The Standard Therapy
0.77
± 0.80
3-month Follow Up
Group
Value
95% CI
The LARA Therapy
0.61
± 0.72
The Standard Therapy
0.96
± 1.37
Timed 10-meter WalkSecondary· Baseline, Post-intervention evaluation at 3 weeks, and 3-months after the end of intervention
We measure the time one takes to complete a 10-meter walk at baseline evaluation, the post-intervention evaluation, and the 3-month follow up evaluation. Participants are instructed to walk at a distance of 10-meter over a level surface with 2 meters for acceleration and 2 meters for deceleration. Participants are instructed to walk at their comfortable or normal speed over the entire distance. Participants are timed once the first foot passes the acceleration path; the time is stopped once the first foot enters the deceleration path. The lower scores indicate a better outcome.
Baseline Evaluation
Group
Value
95% CI
The LARA Therapy
18.8
± 9.7
The Standard Therapy
23.4
± 9.1
Post-Intervention Evaluation
Group
Value
95% CI
The LARA Therapy
15.2
± 7.5
The Standard Therapy
14.4
± 5.0
3-month Follow Up
Group
Value
95% CI
The LARA Therapy
11.8
± 4.4
The Standard Therapy
11.8
± 3.7
Box and Blocks TestSecondary· Baseline, Post-intervention evaluation at 3 weeks, and 3-months after the end of intervention
We measured the Box and Blocks Test scores at baseline evaluation, the post-intervention, and at the 3-month follow up evaluation. Participants are instructed to move as many blocks as possible, one at a time, from one compartment in a box to a second compartment over a divider for a period of 60 seconds; each block that is moved is counted, and multiple blocks moved at the same time are counted are counted as a single block. The higher scores indicate a better outcome.
Baseline Evaluation
Group
Value
95% CI
The LARA Therapy
8.5
± 10.8
The Standard Therapy
11.9
± 13.6
Post-Intervention Evaluation
Group
Value
95% CI
The LARA Therapy
23.5
± 19.2
The Standard Therapy
22.1
± 22.7
3-month Follow Up
Group
Value
95% CI
The LARA Therapy
53.4
± 31.8
The Standard Therapy
45.8
± 44.6
Sponsor's own description
This study will test the effectiveness of a new lever drive wheelchair, LARA - Lever Actuated Resonance Assistance. LARA facilitates patients in performing a high amount of practice using their moderate to severely impaired upper extremity after stroke.
Investigators will recruit 44 subjects with subacute strokes to participate in the study through the acute rehabilitation unit of the UC Irvine Douglas Hospital. Study participants will be randomized into 2 groups: LARA therapy group or standard therapy group. The LARA therapy group will use LARA to propel themselves to therapy appointments in the unit and to play video games with the affected upper extremity for 30 mins / day. The standard therapy group will use a standard wheelchair to propel themselves using their unaffected upper and lower extremities. They will be asked to perform a matched duration of standard arm exercises for 30 mins/ day. This program of standard arm exercises was developed by an OT at the Rehabilitation Institute of Chicago which consists of graded-difficulty table-supported exercises.
This study will have 3 assessment visits: baseline, 3 weeks after therapy or upon discharge from the acute rehabilitation unit if sooner, and a 3-month follow up.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06371937 — iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease
· recruiting
NCT06107010 — Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Sub
· NA
· recruiting
Other University of California, Irvine trials
Trials by the same sponsor.
NCT06952725 — Chatbot for Online Support Groups to Treat Tobacco Addiction
· NA
· not yet recruiting
NCT07167862 — Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound
· Phase 4
· not yet recruiting
NCT07527325 — Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
· Phase 2
· not yet recruiting
NCT07391891 — Musical Mindfulness for Pain in the ED Waiting Room
· NA
· not yet recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
Last refreshed: 21 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02830893.